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Background: We assessed the effectiveness of perioperative MAGIC-style chemotherapy in our series focused on
the tumor regression grade and survival rate.
Methods: We conducted a retrospective study of 53 patients following a perioperative regimen of epirubicin,
cisplatin, and fluorouracil or capecitabine (ECF/X). Forty-four (83 %) neoplasias were located in the stomach and 9
(17 %) were located at the esophagogastric junction. Perioperative chemotherapy completion, resection, TNM
staging, the tumor regression grade (Becker’s classification) and survival were analyzed.
Results: Forty-five patients (85 %) completed the 3 preoperative cycles. R0 resection was achieved in 42 (79 %)
patients. Thirty-five (66 %) patients completed the 3 postoperative cycles. Nine carcinomas (17 %) were considered
major responders after preoperative chemotherapy. With multivariate analysis, only completion of perioperative
chemotherapy (HR: 0.25; 95%CI: 0.08 – 0.79; p = 0.019) was identified as an independent prognostic factor for
disease-specific survival. However, the protective effect of perioperative therapy was lost in patients with ypT3-4
and more than 4 positive lymph nodes (HR: 1.16; 95%CI: 1.02 – 1.32; p = 0.029). The tumor regression grade
(major vs minor responders) was at the limit of significance only with univariate analysis. The 5-year overall and
disease-specific survival rates were 18 % and 22 % respectively.
Conclusions: The percentage of major responder tumors after preoperative chemotherapy was low.
Completion of perioperative ECF/X chemotherapy may benefit patients with gastric carcinomas that do not
invade the subserosa with few positive lymph nodes.
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In Europe, gastric carcinoma patients have an average
5-year survival rate of approximately 30 %, although
there is wide variation among and within countries [1].
The prognosis in the absence of peritoneal or distant
dissemination continues to be poor when lymph node
(LN) invasion exists, even when an R0 surgical resection
with extended lymphadenectomy is achieved [2, 3]. The
effects of extended D2 lymphadenectomy on disease-free* Correspondence: fj.lacueva@umh.es
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unless otherwise stated.survival have not been well established in Western
countries [4, 5]. However, some current clinical guide-
lines recommend a spleen and pancreas preserving D2
lymphadenectomy [6, 7].
Different strategies have been developed to improve
the poor prognosis associated with radical surgical resec-
tion of localized gastric cancer. Adjuvant radiochemo-
therapy, which improved the median overall survival
rates in the INT 0116 prospective randomized clinical
trial [8] has been questioned in patients with lymph
node negative disease and after D2 lymphadenectomies
[9, 10]. Adjuvant chemotherapy has been consistently
effective after D2 lymphadenectomies in prospective,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Mingol et al. BMC Surgery  (2015) 15:66 Page 2 of 10randomized clinical trials involving only Eastern popula-
tions [11, 12]. Thus, perioperative treatment including
neoadjuvant chemotherapy (NAC) has emerged as the
most attractive approach. In fact, the MAGIC [13] and
FNCLCC-FFCD [14] prospective randomized clinical
trials have found positive effects of the use of NAC on
the curative resection rates, disease-free survival and
overall survival.
Nevertheless, little is known about tumor regression
after neoadjuvant chemotherapy regimen of epirubicin,
cisplatin, and fluorouracil or capecitabine (ECF/X), al-
though partial or minimal regression has been reported
in 54 % of gastric carcinomas [15]. Assessment of the
histopathological changes after NAC is the best method
for evaluating tumor response to chemotherapy [16–18]
and recent data have shown that complete or subtotal
tumor regressions are the only independent prognostic
factors for survival [19].
In this study, we assessed the effectiveness of the
MAGIC perioperative chemotherapy regimen by analyzing
the tumor regression grade, and survival rate.
Patients and methods
From March 2006 to December 2012 patients with
stages II and III gastric and esophagogastric junction
(EGJ) carcinomas underwent a perioperative MAGIC
regimen chemotherapy at the Elche University Hospital
and the Vega Baja Hospital. Patients showing symptoms
of outlet obstruction or morbidity that precluded
chemotherapy were excluded. The diagnostic and sta-
ging workup included an upper endoscopy with biopsy
and a CT scan for all patients. After 2008, EUS was usually
performed unless carcinomatosis or distant metastases
were suspected based on CT scan. Staging laparoscopy
was mostly indicated when CT or EUS showed signs of
linitis, tumor invasión of adjacent structures or ascitis.
Written informed consent was obtained from all patients.
This study was approved by the ethics committee of
the University Hospital of Elche.
The following clinical variables were analyzed in this
study: age, gender, location, completion and morbidity
after preoperative chemotherapy, type of gastrectomy or
esophagectomy, extent of LN dissection as stated by the
surgeon, surgical morbidity and mortality, completion
and morbidity of postoperative chemotherapy, recurrence,
and overall and specific survival. The histopathological vari-
ables analyzed were the depth of invasion (ypT), total and
positive LNs retrieved, LN staging (ypN), carcinomatosis,
peritoneal lavage cytology, liver metastasis (ypM), histo-
logical type, grade, and tumor regression grade according
to Becker’s classification [17]. Tumors with complete re-
gression (grade 1a) or subtotal (<10 % of residual tumor)
regression (grade 1b) were considered major responders.
Tumors with partial (10–50 % residual tumor) regression(grade 2), or with minimal or no regression (>50 % residual
tumor) (grade 3) were classified as minor responders.
Gastric and EGJ tumors were staged according to the
7th edition International Union Against Cancer (UICC)
TNM pathological classification.
Treatment and follow-up
ECF/X regimen chemotherapy was administered for 3 cycles
preoperatively and three cycles postoperatively. Each 3-
week cycle consisted of epirubicin (E) (50 mg per square
meter of body-surface area) by intravenous bolus on day 1,
cisplatin (C) (60 mg per square meter) intravenously with
hydration on day 1, and fluorouracil (F) (200 mg per square
meter) daily for 21 days by continuous intravenous infusion
or capecitabine (X) twice a day (625 mg per square meter)
for 21 days [20].
After preoperative chemotherapy subtotal or total
gastrectomy was undertaken in gastric or type III eso-
phagogastric junction (EGJ) carcinomas. In patients
with type I or II EGJ carcinomas, an Ivor Lewis partial
esophagectomy was performed. Perigastric lymph node
stations (1 to 6) were removed in D1 lymphadenec-
tomies. Additionally, lymph node stations 7, 8a, 9, and
11p were removed in modified D2 lymphadenectomies.
Inferior periesophageal and subcarinal lymph nodes
were also removed in EGJ type I or II carcinomas. D1
or modified D2 lymphadenectomies were chosen ac-
cording to the surgeon’s criteria.
Routine follow-up examinations consisted of a clinical
interview and blood analyses including tumor markers
CEA, CA 19.9 and CA125 every 3 months for the first
2 years after surgery and every 6 months thereafter. CT
scans were performed every 6 months the first 2 years
after surgery and yearly thereafter.
Statistical analysis
A Kaplan Meier survival analysis was performed using a
log-rank test to estimate differences in the 5-year disease-
specific survival rates. Multivariate survival analysis was
performed using a Cox regression model. Prognostic fac-
tors were compared using hazard ratios with a 95 % confi-
dence interval. To identify independent risk factors and to
control for possible bias from patients diagnosed as M1
over the course of perioperative treatment, a Cox regres-
sion analysis (stratified by ypM) was performed. The model
included variables identified by univariate survival analysis
as more influential. SPSS for Windows version 20 was used
for the statistical analysis.
Results
Fifty-three patients were included in the study. The
clinical characteristics of the patients are summarized
in Table 1. Sixteen patients (30.2 %) were older than
70 years of age. EUS was performed in 32 (60.4 %)
Table 1 Demographics of the series
Patients N = 53
Age 64 (38–78)
Sex
Male 36 (67.9 %)
Female 17 (32.1 %)
Tumor location
EG Junction 9 (17 %)
Upper/Middle third 20 (37.7 %)
Distal 22 (41.5 %)
Linitis 2 (3.8 %)
Three preoperative cycles completed 45 (84.9 %)
Three postperative cycles completed 35 (66 %)
Resection
R0 42 (79.2 %)
Unresected or Paliative 11 (20.8 %)
Lauren’s histological type
Intestinal 22 (59.5 %)
Diffuse/Signet ring cell 15 (40.5 %)
Grade
Well or moderately differentiated 14 (37.8 %)
Poorly differentiated or undifferentiated 23 (62.2 %)
ypT
T0-2 16 (33.3 %)
T3-4 32 (66.7 %)
ypN
N0 17 (35.4 %)
N1 8 (16.7 %)
N2-3 23 (47.9 %)
ypM
M0 42 (80.8 %)
M1 10 (19.2 %)
Lymph nodes analyzed
< 15 25 (52.1 %)
≥ 16 23 (47.9 %)
Tumor regression grading
1a-b 9 (17.3 %)
2–3 43 (82.7 %)
Recurrence #
No 16 (38.1 %)
Yes 26 (61.9 %)
Recurrence #: In R0 and M0 patients
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with 6 laparoscopies occurring after EUS. Neoplasias
were located in the stomach in 44 (83 %) cases and at
the esophagogastric junction in 9 (17 %) cases.Perioperative chemotherapy
Forty-five (84.9 %) patients completed the 3 preoperative
cycles. Ten (18.9 %) patients developed grade 3 or 4
hematologic toxicity, which delayed the administration
of the next chemotherapy cycle in 6 cases and caused
early termination of chemotherapy in 2 (3.8 %) patients.
One patient died from a pulmonary embolism. Ten
(18.9 %) patients developed grade 3 or 4 non-hematologic
toxicity, which forced an end to chemotherapy in 7
(13.2 %) cases and delayed administration of the next
chemotherapy cycle in 2 patients.
Thirty-five (66 %) patients received the 3 postoperative
cycles, and thus, they completed all the perioperative
treatment. Eleven of those patients developed hematologic
toxicity that caused only a delay in the administration
of the next cycle. One patient developed grade 3 or 4
non-hematologic toxicity that caused a delay of the
next cycle. Nine (17 %) patients were shifted to another
chemotherapy regimen, and 2 (3.8 %) patients started a
radiochemotherapy Macdonalds’s schema. Reasons for
changing the chemotherapy regimen were evidence of
residual or advanced disease after surgery in 6 patients,
toxicity in 2 patients, and patient’s preference in one
case. In case of advanced or residual disease, all pa-
tients were shifted to docetaxel, cisplatin and fluoro-
uracil (DCF regimen). Seven (13.2 %) patients did not
undergo postoperative treatment.
Surgery
Peritoneal carcinomatosis, pancreatic infiltration or liver
metastasis at the time of surgery precluded resection in
4 (7.5 %) patients. Resection was accomplished in 48 pa-
tients (90.6 %). Six partial esophagectomies, 9 subtotal
gastrectomies and 33 total gastrectomies were per-
formed. An R0 resection was initially obtained in 44 pa-
tients, but positive peritoneal lavage cytology was
identified postoperatively in 2 of these patients (ypM1);
therefore R0 resection was ultimately achieved in 42
(79.2 %) patients. R1 resection was obtained in 1 patient,
with a positive proximal margin and several localized
peritoneal nodules on the pancreatic surface. R2 resec-
tion was performed in 3 patients; one received only a
single cycle of preoperative chemotherapy and also
showed several localized peritoneal nodules on the pan-
creatic surface. The laparotomy findings of ypM1 patients
are detailed in Table 2.
No significant correlation was found between extent of
the lymph node dissection stated by the surgeon and the
number of lymph nodes retrieved by the pathologist.
Modified D2 lymphadenectomy was more frequently
performed than D1 (38 vs 10 patients), but 16 or more
lymph nodes were harvested in only 18 of the 38
(47.4 %). Conversely, at least 16 lymph nodes were har-
vested in 5 of the 10 (50 %) D1 lymphadenectomies







#2 np No R0 ypT4aN2. TR 3. PLC+
#6 np No no Carcinomatosis.
#7 uT4aN0 No R2 ypT3aN3b. TR 3.
Several + nodules on
pancreatic surface.
#11 np No R2 ypT3aN3a. TR 3.
Several + nodules on
pancreatic surface.
#14 np Yes. No findings R1 ypT4aN3a.TR 3. Margin
+. Several + nodules on
pancreatic surface.
#31 np No R0 ypT4aN3a. TR 3. PLC+
#35 uT4aN2 No no Liver metastasis
#38 uT4aN0 No no Pancreatic infiltration.
Several + nodules on
mesocolon. PLC+
#49 uT4aN0 No R2 ypT4aN3a.TR 3.
Carcinomatosis.





USE: Ecoendoscopy. uT1: mucosa and submucosa, uT2: muscular, uT3: subserosa,
uT4a: serosa, np: not performed
NAC: Neoadjuvant chemotherapy. PLC: peritoneal lavage cytology
TR: tumor regression grade





#3 Gastric (A) np pT0N0 1a Death at 5th month due to
subdural hematoma
#8 GEJ SWT-I uT3N1 pT2N0 1b No
#15 Gastric (C) uT2N1 pT1b 1b No
#16 GEJ SWT-II uT4aN0 pT2N0 1b Local. Peritoneal
#25 Gastric (F) uT2N1 pT1bN0 1b Pleura. Peritoneal
#26 Gastric (C) uT4aN1 pT0N0 1a No
#27 Gastric (C) uT4aN1 pT2N0 1b No
#37 Gastric (A) uT4aN1 pT4aN0 1b Death at 9th month due to
cardiopathy
#45 Gastric (A) np pT4aN0 1b Regional. Peritoneal
(A): Antrum, (C): Corpus, (F): Fundus
USE: Ecoendoscopy. uT1: mucosa and submucosa, uT2: muscular, uT3:
subserosa, uT4a: serosa, np: not performed
TR: tumor regression, 1a: complete, 1b: subtotal
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37 (77.1 %) patients.
The morbidity after resection was 20.8 %. The surgical
mortality was 0 %.
Pathological findings
The pathological characteristics of the tumors are detailed
in Table 1. Twenty-four (50 %) carcinomas were staged as
pT4. The median number and range of the retrieved
lymph nodes was 14.5 (5-43). Thirty-one (64.6 %) of the
resected specimens had positive lymph nodes.
Nine cases (17 %) were considered major responders
after preoperative chemotherapy (2 with complete and 7
with subtotal tumor regression) (Table 3). In addition, 2
patients showed complete or subtotal tumor regression
but also had positive lymph nodes and they were classified
as minor responders. In 31 (64.6 %) patients minimal or
no tumor regression was observed (Tables 2 and 4). Peri-
toneal lavage cytology was performed in 36 (69 %) patients
and was positive in 4 (11.1 %).
The major and minor tumor responders are detailed
in Tables 3 and 4. Among patients with R0 resection
who were classified as minor responders to chemotherapy,
4 tumors were classified as stage IA (1 patient) and stage
IB (3 patients) after the pathological study but 2 of themwere classified as stage IIA and IIIB by EUS before the
treatment’s onset. Five of the 23 (21.7 %) patients staged
as uT4 presented with M1 disease at surgery.Survival analysis
The median follow-up of the series was 19 (3–68)
months and the median follow-up of the patients alive
was 43 (9–68) months. Seventy-nine percent of patients
died or were followed for more than 2 years. The 5-year
overall and disease-specific survival rates were 18 % and
22 % respectively (Fig. 1a and b).
After univariate analysis of the 5-year disease-specific
survival, the completion of perioperative chemotherapy
(p < 0.001), completion of NAC (p < 0.007), depth of in-
vasion (ypT0-2 vs ypT3-4) (p < 0.01), LN staging (ypN0
vs. ypN2-3) (p < 0.001), number of positive LNs (p <
0.001), and metastasis (ypM0 vs. ypM1) (p < 0.001) were
shown to be significant (Fig. 2a–c). LN staging (ypN1 vs.
ypN2-3) (p < 0.051) and tumor regression grade (major
vs. minor responders) (p < 0.051) were at the limit of sig-
nificance (Fig. 2c, 2d).
Of the 9 patients with complete or subtotal tumor re-
gression (Becker’s grade 1a and 1b), 3 patients died due
to recurrence (33.3 %), 4 patients were disease-free after
3 or more years of follow-up (44.4 %), and 2 patients
died during early follow-up due to pulmonary thrombo-
embolism (5th month) and cardiomyopathy (9th month).
Of the 33 patients in which R0 resection was achieved
but partial, minimal or no tumor regression (Becker’s
grade 2 and 3) was observed, 23 (69.7 %) had recurrence,
10 (30.3 %) were disease-free, and 1 patient died due
renal cancer progression. The 5-year disease-specific
survival rate of patients with regressions grades 1a and
Table 4 Patients with R0 resection and partial or minor response to chemotherapy
Case Location Use (uTN) ypTNM TR Recurrence
#1 Gastric (F) np T1bN1 3 Local regional. Brain
#4 Gastric (C) np T3N3a 3* Peritoneal
#9 GEJ SWT-I np T2N0 2 Local regional
#10 Gastric (C) np T4aN0 3 Local regional
#12 GEJ SWT-III np T4bN3b 3 Liver. Adrenal
#13 Gastric (C) uT4aN0 T3N0 3 No
#17 Gastric (C) np T4aN0 3 No
#18 Gastric (L) uT4aN1 T0N3b 1a* Pleura
#19 Gastric (F) uT2N1 T2N2 3 No
#20 GEJ SWT-II uT4aN1 T2N1 2 No. Death at 52th month due to renal cancer
#21 Gastric (A) uTxN1 T4aN2 2 Local regional
#22 Gastric (C) uT4aN1 T3N2 3 Local regional
#23 Gastric (A) uT4aN2 T4aN3a 3 Peritoneal
#24 Gastric (C) np T3N2 2 Peritoneal. Pleura. Bone
#28 Gastric (A) uT4aN0 T4aN2 3* Lung
#29 Gastric (C) uT4aN0 T4aN0 3* Liver
#30 Gastric (C) uT4aN1 T4aN2 3* Peritoneal
#32 Gastric (A) uT3N0 T1bN0 3* No
#33 Gastric (L) uT3N1 T3N1 2 Peritoneal. Pleura
#34 Gastric (A) uT4aN2 T2N0 3* No
#36 Gastric (A) uT4aN2 T4aN2 3 Liver
#39 Gastric (A) uT3N1 T2N1 3 No
#40 Gastric (A) np T4aN0 3* No
#41 GEJ SWT-II np T4aN1 3 No
#42 Gastric (A) uT4aN1 T3N3a 3 Bone
#43 GEJ SWT-II uT4aN1 T4bN1 3 Local regional
#44 Gastric (A) uT4aN1 T4aN3a 3 Local regional
#46 Gastric (A) uT2N1 T1bN1 1b* Liver. Lung
#47 Gastric (C) np T4aN3a 3* Local regional
#48 Gastric (C) np T4aN1 3 Lung
#50 Gastric (A) np T4aN2 3 Peritoneal
#52 GEJ SWT-III np T4bN3 3 Peritoneal
#53 Gastric (C) uT4aN1 T4aN2 2 No
(A): Antrum, (C): Corpus, (F): Fundus, (L): linitis
USE: Ecoendoscopy. uT1: mucosa and submucosa, uT2: muscular, uT3: subserosa, uT4a: serosa, np: not performed
TR: tumor regression, 2: partial, 3: minimal, 3*: no regression, 1a* and 1b*: complete or subtotal tumor regression but positive lymph nodes
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and 3 (Fig. 2d).
A multivariate survival analysis stratified by ypM was
performed including the following variables: completed
vs. incompleted perioperative chemotherapy, number of
positive LNs, ypT3-4 vs. ypT < 3, major vs. minor tumor
regression grade, and an interaction factor composed of
the completion of perioperative chemotherapy, ypT, and
the number of positive LNs (Table 5). Only completion
of perioperative chemotherapy (HR: 0.25; 95 % CI: 0.08–0.79; p = 0.019) was identified as an independent prog-
nostic factor for the 5-year disease-specific survival.
However, the completion of perioperative chemotherapy,
depth of invasion and number of positive LNs were re-
lated, and patients with ypT3-4 and more than 4 positive
LNs did not show increased survival rates even if they
completed perioperative chemotherapy (HR: 1.16; 95 %
CI: 1.02–1.32; p = 0.029). The 5-year disease-specific sur-
vival rate of the patients who completed perioperative
chemotherapy was 29.6 % (Fig. 2a).
Fig. 1 Kaplan-Meier (a) overall survival and (b) disease-specific survival of the series
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Fig. 2 Disease-specific survival of patients according to completion of perioperative chemotherapy, the lymph node status, depth of invasion and
tumor regression grade (major and minor responders)
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Table 5 Multivariate survival analysis stratified by ypM
HR (CI 95 %) P value
Completed perioperative treatment (yes/no) 0.25 (0.08–0.79) 0.019
Number of positive lymph nodes 1.02 (0.93–1.13) 0.653
ypT3-4 vs ypT1-2 1.34 (0.42–4.30) 0.622
Major vs minor regression grade after NAC 0.91 (0.21–3.94) 0.900
Interaction factor: Completed perioperative
treatment • ypT3-4 • ypN > 4
1.16 (1.02–1.32) 0.029
Interaction factor: Patients that completed perioperative treatment with ypT3-4
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In this study, a high percentage of patients completed
preoperative chemotherapy (85 %), and a high per-
centage of R0 resection was achieved (79 %). Comple-
tion of preoperative chemotherapy was higher in the
perioperative-chemotherapy arm of the MAGIC trial
(91 %), but R0 resection was achieved in only 69 % of
the cases. Additionally, a higher percentage of our patients
completed all 3 postoperative cycles (66 %) compared to
those in the MAGIC trial (42 %) [13]. In our study, one
patient died during the neoadjuvant period due to pul-
monary embolism. It has been reported that up to 3 %
of lethal thrombo-embolic episodes occur during the
preoperative period [15].
Completion of perioperative chemotherapy was the
only independent prognostic factor in our study, and it
was associated with a significant improvement of the
5-year specific-survival rate of these patients. However,
the beneficial effects of perioperative chemotherapy were
not observed in patients that had both tumors infiltrating
subserosa or beyond and who had more than 4 positive
lymph nodes. These data suggest that the impact of the
ECF/X regimen on survival is mild. The overall and 5-year
disease-specific survival rate of the series was quite poor
compared to the 36 % obtained in the perioperative-
chemotherapy group of the MAGIC trial, despite the
higher percentage of R0 resection achieved in our study.
This difference cannot be easily explained by different
pathological findings, because the number of patients with
tumors reaching the serosa or beyond (50 %), and tumors
without lymph node metastasis (35 %) were very similar in
this study and the MAGIC trial (48 % and 31 % respect-
ively). Nevertheless, the higher percentage of pN3 tumors
found in our study (27 % vs. 16 %) may lead to poorer 5-
year survival rates. Finally, a recent study [21] reported a
similar overall survival to that achieved in the MAGIC
trial but also the percentage of pN2-pN3 was significant
lower (29 %) than the shown in our study (48 %).
Little information is available on the tumor regression
grade produced by the preoperative ECF/X regimen ingastric cancer [15, 22]. These reported studies used dif-
ferent classification systems to assess tumor regression,
which prevents direct comparisons with our findings. In
our study, complete or subtotal regression was only ob-
served in 17 % of carcinomas, but these patients had
better 5-year survival rates compared to those with par-
tial or minor tumor regression. This relatively low per-
centage of major responders has been observed in other
gastric cancer studies in which different chemotherapy
regimens or radiochemotherapy schemas were preopera-
tively administered [19, 23, 24]. Notably, patients with
subtotal or even complete tumor regression of the pri-
mary tumor may also have LN metastasis which
occurred in 2 of the patients in this study, a finding that
has previously been reported by others [25]. Major
tumor regression was consistently supported comparing
the uTN to ypTN classifications in this group of carcin-
omas. Several studies agree that complete or subtotal re-
gression, but not partial regression, is associated with
higher disease-free survival rates [19, 24, 25]. In a large
series analyzing tumor regression after different neoadju-
vant cisplatin-based regimens [19], multivariate analysis
identified only complete or subtotal tumor regression
and ypN status as independent prognostic factors for
survival. Additionally, no difference in the mean survival
was identified between patients with partial and minor
tumor regression, which is why we combined these pa-
tients into one cohort. It must be highlighted that tumor
regression was minimal or absent in a large percentage
of our patients (67 %). In a similar way, another study of
perioperative ECF/X chemotherapy reported less than
50 % tumor regression in 54 % of the cases [15]. This
fact suggests that patients with minor or no regression
tumors may be at a risk of developing micrometastasis
or peritoneal seeding during the neoadjuvant period. In
a study of locally advanced gastric carcinomas in which
a second laparoscopy was performed after neoadjuvant
chemotherapy, free peritoneal tumor cells were detected
in 24 % of patients with a previous negative staging
laparoscopy, which confirms that the risk is real [26].
It is crucial to identify new biomarkers that predict
tumor response or resistance to chemotherapy regimens
to avoid the delay of potentially curative surgery in pa-
tients with non-responsive tumors [27, 28]. HER2
overexpression showed to be a useful biomarker in in-
operable or metastatic gastric and esophagogastric
carcinomas for selective treatment with trastuzumab
in combination with chemotherapy [29]. On the other
hand, ERCC1 nuclear protein expression in clinico-
pathological studies [30] and leptin expression in
in vitro studies [31] have been associated with poor
pathologic response to platinum-based chemotherapy
regimens. Therefore, biomarkers of drugs resistance
should be included in future clinical trials.
Mingol et al. BMC Surgery  (2015) 15:66 Page 9 of 10EUS was useful in selecting the patients included in
the perioperative MAGIC regimen except in 2 cases.
EUS is recommended for workup staging in some clin-
ical guidelines [6, 7], and it is reportedly more accurate
in staging T3 and T4 tumors but less reliable for N sta-
ging [32]. However, EUS was not useful in appropriately
selecting the uT4a tumors that should undergo a staging
laparoscopy for detection of carcinomatosis. Thus, 22 %
of the uT4a tumors were staged as upM1 after surgery, a
result that is similar to the findings reported by other
authors [33].
The most important limitation of this study was the
relative small sample size. Other studies confirm how
difficult it can be to recruit gastric cancer patients for
perioperative chemotherapy, which was evident in the
two largest studies with patients from 50 and 28 par-
ticipant centers that required 8 years to close [13, 14].
Another study carried out in one institution assessed
the perioperative MAGIC regimen in one hundred
gastro-esophageal carcinomas, but only 32 gastric tumors
were included [15].
Conclusion
Completion of perioperative ECF/X chemotherapy was
an independent prognostic factor for the 5-year disease-
specific survival, although higher survival rates were im-
paired in patients with tumors that were invading the
subserosa or beyond and more than 4 positive lymph
nodes. A small proportion of patients with gastric car-
cinomas showed complete or subtotal tumor regression
after perioperative ECF/X chemotherapy.
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